Skip to main content
SpringerLink
Log in

Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use

  • Published:
Annals of Clinical Psychiatry

Abstract

To review the literature on the pharmacologic treatment of posttraumatic stress disorder (PTSD), with a focus on reports of antipsychotic use for this illness. A MEDLINE search (1966-Oct 2002) for English only articles about pharmacologic treatment of PTSD. Antipsychotic medications are being used with some frequency for PTSD. There are few studies and scant evidence to recommend the traditional antipsychotics. There are a number of reports (mostly case reports and open trials) in which atypical antipsychotics improved sleep and decreased the frequency of nightmares and flashbacks. Some studies showed global improvement across symptom clusters. The newer atypical antipsychotics show promise for the treatment of PTSD, mainly ameliorating intrusive symptoms. The paucity of double-blind studies prevents firm conclusions, however, this class of medications may be useful particularly for refractory symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Solomon S, Davidson JRT: Trauma: Prevalence, impairment, service use, and cost. J Clin Psychiatry 1997; 58(9):5-11

    Google Scholar 

  2. Hidalgo RD, Davidson JRT: Posttraumatic stress disorder: Epidemiology and health-related considerations. J Clin Psychiatry 2000; 61(7):5-13

    Google Scholar 

  3. Kessler RC: Posttraumatic stress disorder: The burden to the individual and to society. J Clin Psychiatry 2000; 61(5):4-14

    Google Scholar 

  4. Ferrada-Noli M, Asberg M, Ormstad K, Lundin T, Sundbom E: Suicidal behavior after severe trauma, Pt 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J Trauma Stress 1998; 11:103-112

    Google Scholar 

  5. Breslau N, Davis GC, Andreski P, Peterson E: Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991; 48:216-222

    Google Scholar 

  6. Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P: Trauma and posttraumatic stress disorder in the community. The 1996 Detroit area survey of trauma. Arch Gen Psychiatry 1998; 55:626-632

    Google Scholar 

  7. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048-1060

    Google Scholar 

  8. Breslau N: The epidemiology of posttraumatic stress disorder: What is the extent of the problem? J Clin Psychiatry 2001; 62(17):16-22

    Google Scholar 

  9. Davidson JR, Hughes D, Blazer DG, George LK: Posttraumatic stress disorder in the community: An epidemiological study. Psychol Med 1991; 21:713-721

    Google Scholar 

  10. Breslau N, Chilcoat HD, Kessler RC, Davis GC: Previous exposure to trauma and PTSD effects of subsequent trauma: Results from the Detroit Area Survey of Trauma. Am J Psychiatry 1999; 56:902-907

    Google Scholar 

  11. Bromet E, Sonnega A, Kessler RC: Risk factors for DSMIIIR PTSD: Findings from the National Comorbidity Survey. Am J Epidemiol 1998; 147:343-361

    Google Scholar 

  12. Center for Disease Control. Vietnam Experience Study: Psychological and Neuropsychological Evaluation. Atlanta, GA: Center for Disease Control; 1988

    Google Scholar 

  13. Davidson JRT: Pharmacotherapy of posttraumatic stress disorder: Treatment options, long-term follow-up, and predictors of outcome. J Clin Psychiatry 2000; 61(5):52-56

    Google Scholar 

  14. Hageman I, Andersen HS, Jorgensen MB: Posttraumatic stress disorder: A review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001; 104:411-422

    Google Scholar 

  15. Cyr M, Farrar K: Treatment of posttraumatic stress disorder. Ann Pharmacother 2000; 34:366-376

    Google Scholar 

  16. Stein DJ, Zungu-Dirwayi N, van der Linden GJH, Seedat S: Pharmacotherapy of posttraumatic stress disorder. Cochrane Lib 2002; 2:1-37

    Google Scholar 

  17. Tucker P, Trautman R: Understanding and treating PTSD: Past, present, and future. Bull Meninger Clin 2000; 64(3, Suppl A):37-51

    Google Scholar 

  18. Connor KM, Davidson JRT: Pharmacotherapy for posttraumatic stress disorder: Beyond the SSRIs. Intl. Drug Ther 2002; 37(6):41-48

    Google Scholar 

  19. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, McFarlane AC, Shalev AY: Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2000; 61(5):60-66

    Google Scholar 

  20. Post RM, Weiss SRB, Smith M, Li H, McCann U: Kindling versus quenching: Implications for the evolution and treatment of in posttraumatic stress disorder. Ann NY Acad Sci 1997; 821:285-295

    Google Scholar 

  21. Wolfe ME, Alavi A, Mosnaim AD: Posttraumatic stress disorder in Vietnam veterans: Clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23:642-644

    Google Scholar 

  22. Lipper S, Davidson JRT, Grady TA, Edinger JD, Hammett EB, Mahorney SL, Cavenar JO, Jr.: Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics 1986; 27:849-854

    Google Scholar 

  23. Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52:361-364

    Google Scholar 

  24. Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999; 12:395-401

    Google Scholar 

  25. Kitchner I, Greenstein R: Low dose lithium carbonate in the treatment of posttraumatic stress disorder: Brief communication. Mil Med 1985; 150:378-381

    Google Scholar 

  26. Berlant JL: Topiramate in posttraumatic stress disorder: Preliminary clinical observations. J Clin Psychiatry 2001; 62(17):60-63

    Google Scholar 

  27. Berlant JL, van Kammen DP: Open-label topirimate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry 2002; 63(1):15-20

    Google Scholar 

  28. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45:1226-1229

    Google Scholar 

  29. Hamner MB, Bodrick PS, Labbate LA: Gabapentin in PTSD: A retrospective clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13:141-146

    Google Scholar 

  30. Braun P, Green D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51:236-238

    Google Scholar 

  31. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY: Treament of recent trauma survivors with bensodiazepines: A prospective study. J Clin Psychiatry 1996; 57:390-394

    Google Scholar 

  32. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced post-traumatic stress disorder. J Clin Psychiatry 1990; 51:206-209

    Google Scholar 

  33. Famularo R, Kinscherff R, Fenton T: Propranolol treatment for childhood post-traumatic stress disorder, acute type: A pilot study. Am J Dis Child 1988; 142:1244-1247

    Google Scholar 

  34. Friedman MJ, Southwick SM: Towards pharmacotherapy for PTSD. In Friedman MJ, Charney DS, Deutch AY, eds. Nerobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott–Raven; 1995:465-481

    Google Scholar 

  35. Kinzie JD, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177:546-550

    Google Scholar 

  36. Taylor F, Raskind MA: The alpha adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma post-traumatic stress disorder. J Clin Psychopharmcol 2002; 22:82-85

    Google Scholar 

  37. Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER: The alpha adrenergic antaonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: A report of four cases. J Clin Psychiatry 2000; 61(2):129-133

    Google Scholar 

  38. Faustman WO, White PA: Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with post-traumatic stress disorder. J Nerv Ment Dis 1989; 177:154-159

    Google Scholar 

  39. Birklimer LJ, DeVane CL, Muniz CE: Posttraumatic stress disorder: Characteristics and pharmacological response in the veteran population. Compreh Psychiatry 1985; 26(3):304-310

    Google Scholar 

  40. Ciccone PE, Amzarek A, Weisbrot M, Greenstein RA, Olsen K, Zimmerman J: Pharmacotherapy for PTSD. Am J Psychiatry 1988; 145(11):1484-1485

    Google Scholar 

  41. Sernyak MJ, Kosten TR, Fontana A, Rosenheck R: Neuroleptic use in the treatment of posttraumatic stress disorder. Psychiatr Q 2001; 72(3):197-213

    Google Scholar 

  42. Bleich A, Siegel B, Garb R, Lerer B: Posttraumatic stress disorder following combat exposure: Clinical features and psychopharmacological treatment. Br J Psychiatry 1986; 149:365-369

    Google Scholar 

  43. Dillard ML, Bendfeldt F, Jernigan P: Use of thioridazine in posttraumatic stress disorder. South Med J 1993; 86(11):1276-1278

    Google Scholar 

  44. Eidelman I, Seedat S, Stein DJ: Risperidone in the treatment of acute stress disorder in physically traumatized inpatients. Depress Anxiety 2000; 11:187-188

    Google Scholar 

  45. Leyba CM: Risperidone in PTSD. Psychiatr Serv 1998; 49:245-246

    Google Scholar 

  46. Krashin D, Oates EW: Risperidone as an adjunct therapy for posttraumatic stress disorder. Mil Med 1999; 8:605-606

    Google Scholar 

  47. Monnelly EP, Ciraulo DA: Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 1999; 19:377-378

    Google Scholar 

  48. Hamner MB, Ulmer HG, Faldowski RA, Frueh BC, Twomey TJ, Tyson C, Lorberbaum JP, Teneback CC, Huber MG, Arana GW: A randomized, controlled trial of risperidone for psychotic features in PTSD. Int J Neuropsychopharmacol 2000; 3:S141

    Google Scholar 

  49. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA: Olanzapine treatment for posttraumatic stress disorder: An open-label study. Int. Clin Psychopharmacol 2001; 16:331-337

    Google Scholar 

  50. Butterfield M, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JRT: Olanzapine in the treatment of posttraumatic stress disorder. Int Clin Psychopharmacol 2001; 16:197-203

    Google Scholar 

  51. Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 2002; 159:1777-1779

    Google Scholar 

  52. Labatte L, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder. Can J Psychiatry 2000; 45(7):667-668

    Google Scholar 

  53. Prior TI: Treatment of posttraumatic stress disorder with olanzapine. Can J Psychiatry 2001; 46:182

    Google Scholar 

  54. Hamner MB: Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psych 1996; 153(6):841

    Google Scholar 

  55. Friedman MJ: What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? J Clin Psychiatry 2000; 61(Suppl 7):44-51

    Google Scholar 

  56. Southwick SM, Yehuda R, Morgan CA: Clinical studies of neurotransmitter alterations in posttraumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott–Raven; 1995:335-349

    Google Scholar 

  57. DeBellis MD, Chrousos GP, Dorn LD, Burke L, Helmers K, Kling MA, Trickett PK, Putnam FW: Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin Endocrinol Metab 1994; 78:249-255

    Google Scholar 

  58. Davis LL, Suris A, Lambert MT, Heinberg C, Petty F: Post-traumatic stress disorder and serotonin: New directions for research and treatment. J Psychiatry Neurosci 1997; 22:318-326

    Google Scholar 

  59. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258

    Google Scholar 

  60. Tucker P, Trautman R: Understanding and treating PTSD: Past, present, and future. Bull Meninger Clin 2000; 64(3, Suppl A):37-51

    Google Scholar 

  61. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131-134

    Google Scholar 

  62. Weisler RH, Ahearn EP, Davidson JT, Wallace R: Adjunctive use of olanzapine in mood disorders: Five case reports. Ann Clin Psychiatry 1997; 9:259-262

    Google Scholar 

  63. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258

    Google Scholar 

  64. Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60(2):116-118

    Google Scholar 

  65. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM: Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986; 43:691-697

    Google Scholar 

  66. Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988; 45:111-119

    Google Scholar 

  67. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR: Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 2002; 16(4):365-368

    Google Scholar 

  68. Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M: Psychobiological mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:295-305

    Google Scholar 

  69. Thierry AM, Tassin TP, Blanc G, Glowinski J: Selective activation of the mesocortical dopamine system by stress. Nature 1976; 203:242-244

    Google Scholar 

  70. Mantz J, Thierry AM, Glowinski J: Effect of noxious tail pinch on the discharge rate of mesocortical and mesolimbic dopamine neurons: Selective activation of the mesocortical system. Brain Res 1989; 476:377-381

    Google Scholar 

  71. Yehuda R, Southwick S, Giller EL, Ma X, Mason JW: Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992; 180:321-325

    Google Scholar 

  72. Hamner M, Diamond BI: Elevated plasma dopamine in post-traumatic stress disorder: A preliminary report. Biol Psychiatry 1993; 33:304-306

    Google Scholar 

  73. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL: Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003; 28:1-13

    Google Scholar 

  74. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL: Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 2000; 47:1000-1004

    Google Scholar 

  75. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95:3239-3244

    Google Scholar 

  76. Romeo E, Str A, Spalletta G, di Michele F, Hermann B, Hols-boer F, Pasini A, Rupprecht R: Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998; 155:910-913

    Google Scholar 

  77. Crawley JN, Glowa JR, Majewska MD, Paul SM: Anxiolytic activity of an endogenous adrenal steroid. Brain Res 1986; 398:382-385

    Google Scholar 

  78. Wieland S, Lan NC, Mirasedeghi S, Gee KW: Anxiolytic activity of the progesterone metabolite 5alpha-pregnan-3alpha-ol-20-one. Brain Res 1991; 565:263-268

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Willam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin

    Eileen P. Ahearn & Amy Krohn

  2. Duke University Medical Center, Durham, North Carolina

    Kathryn M. Connor & Jonathan R. T. Davidson

Authors
  1. Eileen P. Ahearn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Krohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathryn M. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan R. T. Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eileen P. Ahearn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahearn, E.P., Krohn, A., Connor, K.M. et al. Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use. Ann Clin Psychiatry 15, 193–201 (2003). https://doi.org/10.1023/B:ACLI.0000008173.01153.4e

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:ACLI.0000008173.01153.4e

Search

Navigation